-
Beyond the Data: A Wrist-Worn Sensor in Chest Pain Workup
Carlsbad, California (March 27, 2023) – RCE Technologies, Inc. Check out the Professor Mamas Mamas’s recent interview with Dr. Partho Sengupta. Dr. Sengupta emphasizes the value of continuous biomarkers, the change in the reported values over time, and the future of integrating the technology beyond the emergency department. The interview can be found here: https://www.tctmd.com/videos/beyond-the-data-a-wristworn-sensor-in-chest-pain-workup.6321864168112 TCTMD…
-
RCE at the 17th Annual Biomarkers Symposium
Torrey Pines, California (March 25, 2023) The 17th Annual Biomarkers and Personalized Medicine in Cardiovascular Disease Symposium showcased the latest clinical data, guidelines and evidence related to the clinical application of novel biomarkers in cardiovascular conditions. Topics covered state-of-the-art application of biomarkers in current standards in the prediction, diagnosis and management of cardiovascular diseases, highly…
-
A novel breakthrough in wrist-worn transdermal infrared sensor assessment for acute myocardial infarction
Carlsbad, California (March 19, 2023) – RCE Technologies, Inc.
-
X-ray to CT-Scan and beyond..
March 14, 2023 | RCE.ai Significant developments and evolution of medical device technology have occurred in many fields of medicine. One such area was radiology, and studying history helps us understand how the past shaped the medical industry’s trajectory from conception to impact in patient care. Back in 1895, German physics professor Wilhelm Röntgen discovered…
-
RCE Takes the Stage at the 2023 American College of Cardiology with Exciting Late Breaking Clinical Trial Results
New Orleans, LA (March 6, 2023) – RCE Technologies, Inc’s groundbreaking study titled “A Novel Breakthrough In Wrist-Worn Transdermal Troponin-I-Sensor Assessment For Acute Myocardial Infarction” was presented at the American College of Cardiology – Late Breaking Clinical Trials on March 6, 2023. The presentation was delivered center stage by Dr. Partho Sengupta, Henry Rutgers Professor of…
-
RCE welcomes Ronald P. Karlsberg, MD as clinical advisor
Carlsbad, California (March 2, 2023) – RCE Technologies, Inc. has just announced a major addition to the clinical team: the highly acclaimed Ronald P. Karlsberg, MD, FACC. As a Clinical Professor of Medicine at the prestigious Smidt Heart Institute at Cedars-Sinai and the David Geffen School of Medicine at UCLA, Dr. Karlsberg has established himself as a leader…
-
RCE awarded NSF grant to advance development of heart attack diagnostics
Carlsbad, California (January 16, 2023) – RCE Technologies, Inc. a medical technology company harnessing the power of sensors, machine learning and proprietary algorithms towards heart attack diagnostics, announced today it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Science Foundation (NSF) for $255,892. “It’s an absolute honor to receive this grant from…
-
RCE to present at the 2023 American College of Cardiology – Late Breaking Clinical Trials
Carlsbad, California (December 20, 2022) – RCE Technologies, Inc. has been accepted to present at the American College of Cardiology – Late Breaking Clinical Trials. The presentation titled, “A Novel Breakthrough In Wrist-Worn Transdermal Troponin-I-Sensor Assessment For Acute Myocardial Infarction” will be delivered center stage on March 6, in New Orleans, Louisiana, by Dr. Partho Sengupta, Henry Rutgers…
-
American Heart Association 2022 – RCE presentation
RCE had the honor to present a poster in “The Intersection of Biomarkers and Health Technology ” session series at the American Heart Association’s 2022 conference in Chicago this November. These are preliminary insights towards the development of the transdermal Troponin sensor. The abstract is published in Circulation. 2022;146:A12766
-
RCE featured at innovation showcase
September 14, 2022 | New Brunswick, NJ With rapid transformation of cardiovascular medicine from reactive to preventive, the Rutgers Robert Wood Johnson University Hospital is investing in the vision of a technology-enabled cardiovascular service that will enhance all aspects of the patient journey by leveraging advanced technologies such as innovative devices, robotics and artificial intelligence…